Secondary Logo

Share this article on:

Uterine Leiomyosarcoma: A Review Article

Gockley, Allison A. MD; Rauh-Hain, J. Alejandro MD; del Carmen, Marcela G. MD, MPH

International Journal of Gynecological Cancer: November 2014 - Volume 24 - Issue 9 - p 1538–1542
doi: 10.1097/IGC.0000000000000290
Review Articles

Uterine leiomyosarcomas (LMSs) are rare aggressive tumors, with high recurrence rates, even when confined to the uterine corpus at the time of diagnosis. These tumors are large myometrial masses, which typically spread hematogenously. Patients present with vague symptoms similar to those of patients with leiomyomas. Most patients are diagnosed with LMS postoperatively. In the presence of metastatic disease, complete surgical cytoreduction should be attempted when feasible. Lymphadenectomy should be performed only in patients with nodes suspected of harboring metastatic disease and as part of a cytoreductive effort. There are conflicting data to support adjuvant chemotherapy or radiation therapy for early-stage disease. Patients with advanced-stage disease should receive gemcitabine and docetaxel adjuvant chemotherapy. Patients with recurrent disease are candidates for a wide variety of second-line treatments, of which many are investigational. Although prognosis remains dismal, ongoing studies are investigating the role of advanced imaging, multimodality treatment, prognostic nomograms, and unique biomedical pathways to increase understanding of LMS and improve therapeutic options for patients.

Division of Gynecologic Oncology, Vincent Obstetrics and Gynecology, Boston, MA.

Address correspondence and reprint requests to Marcela G. del Carmen, MD, MPH, Division of Gynecologic Oncology, Vincent Obstetrics and Gynecology, Massachusetts General Hospital, 55 Fruit Street, Yawkey 9 E, Boston, MA 02114. E-mail: mdelcarmen@partners.org.

The authors declare no conflicts of interest.

Received April 14, 2014

Received in revised form August 26, 2014

Accepted August 31, 2014

Uterine sarcomas account for 3% to 8% of all uterine corpus malignancies.1 With the recent reorganization and classification of carcinosarcomas as metaplastic forms of endometrial carcinomas, leiomyosarcomas (LMSs) are now the most common uterine sarcomas. Although rare, the tumors are devastating with poor prognosis and aggressive biology leading to early metastatic spread both locally and distantly. Consensus with respect to prognosis and treatment are lacking. The International Federation of Gynecology and Obstetrics (FIGO) classification and staging system for uterine sarcomas is shown in Table 1.2

TABLE 1

TABLE 1

Back to Top | Article Outline

MATERIALS AND METHODS

MEDLINE was searched for all research articles published in English between January 1, 1980, and April 15, 2014, which reported on patients diagnosed with uterine LMS. Given the rarity of this tumor, studies were not limited by design or number of reported patients. Two hundred sixteen studies were originally identified, and 104 were chosen after limiting the review to those articles focusing on uterine LMS and cross-referencing to eliminate duplication. This review includes the most pertinent of these articles.

Back to Top | Article Outline

EPIDEMIOLOGY

According to the Surveillance, Epidemiology and End Results (SEER) database, the incidence of uterine sarcomas from 1979 to 2001 was 0.36 per 100,000 woman-years and may be increasing among women in the United States.3 However, given the rarity of these tumors, large-scale epidemiologic studies have not been possible. The mean age of diagnosis is 60 years.3 African Americans have a 2-fold higher incidence of LMS as compared with their white counterparts.3 Tamoxifen use for longer than 5 years has also been linked to LMS; however, the absolute risk remains minimal, estimated to be 17 per 100,000 woman-years in breast cancer prevention trials.4

Back to Top | Article Outline

PATHOLOGY

Classically, LMS tumors are large (>10 cm), yellow or tan solitary masses with fleshy soft surfaces and distinct areas of hemorrhage and necrosis. The tumors originate in the myometrium and often encroach on the uterine cavity.5 Histologically, the tumors often exhibit irregular infiltrative borders and vascular invasion.5

Although histopathology criteria remain controversial, greater than 15 mitotic figures per 10 high power fields (HPF), necrosis, and moderate-to-severe cytologic atypia are common.5 Many benign smooth muscle tumors can mimic features of LMS. In rare cases, it may be impossible to differentiate between benign and malignant tumors, and the specimen is designated smooth muscle tumor of uncertain malignant potential. Immunohistochemistry may also be helpful in differentiating LMS from other tumors.

Back to Top | Article Outline

PATHOGENESIS

Leiomyosarcomas generally arise from a solitary lesion as opposed to the extremely rare transformation from benign leiomyomas; however, it is not uncommon to find both growths in a single specimen. Distinct molecular pathways have been identified for LMS and leiomyomas. Although the complete mechanism responsible for LMS tumor development is not known, current research suggests that the tumor is unstable and the result of multiple genetic errors, most commonly, abnormalities in p16, p53, and Ki-67; however, research continues to support extremely heterogeneous patterns.6,7 Because of the genetic instability, aggressive biology, and chemotherapy resistance, LMS may resemble type II endometrial carcinomas and high-grade serous ovarian and fallopian tube carcinomas.

These aggressive tumors are characterized by early dissemination. A study of autopsy data identified metastases to the lung and other distant sites in the absence of lymphatic disease suggesting that hematogenous spread may be the predominant method of dissemination.8 A recent Gynecologic Oncology Group (GOG) study supports this observation, reporting that less than 5% of stage I and II patients exhibited positive nodes.1

Back to Top | Article Outline

CLINICAL PRESENTATION

A SEER database study revealed that most tumors were stage I (68%), whereas 3% and 7% were diagnosed at stages II and III, respectively. Twenty-two percent were diagnosed as stage IV disease.9 Abnormal vaginal bleeding, abdominal pain, vaginal discharge, urinary frequency, constipation, and abdominal distention are some of the nonspecific presenting symptoms of LMS. Early diagnosis is difficult because these symptoms are also frequently reported by women with benign leiomyomas. Some patients may present acutely with hemoperitoneum because of tumor rupture or extrauterine extension.

Back to Top | Article Outline

DIAGNOSIS

Endometrial sampling correctly identifies only 25% to 50% of LMSs preoperatively, which may be because in part of the myometrial origin of the tumors.10 These tumors are most often diagnosed histologically after myomectomy or hysterectomy.

Back to Top | Article Outline

IMAGING

The role of imaging in the diagnosis and management of LMS continues to evolve. Abdomen and pelvic computed tomography (CT) imaging can be useful for visualizing extrauterine disease spread, frequently to the lungs and the liver.11 Despite multiple studies in various imaging modalities, preoperative imaging has not been proven to differentiate between benign and malignant tumors, although research continues to strive toward more accurate methods of differentiating these aggressive tumors from their more benign counterparts. Studies investigating the role of positron emission tomography (PET-CT) in detecting recurrence of LMS have shown that, although PET-CT is sensitive and specific, it provides no significant advantage over conventional imaging.12 However, these studies include patients with carcinosarcoma and endometrial stromal sarcoma so the true use for LMS patients remains unknown.

Back to Top | Article Outline

STAGING

In 2009, FIGO developed a unique staging system for uterine sarcomas2 (Table 1).

Back to Top | Article Outline

PROGNOSIS

The LMS tumors are aggressive and associated with very poor outcomes, even in the setting of early-stage disease. Recurrence rates in LMS are high, estimated to be 53% to 71%.1 In 1 study, patients with stage I and II disease had a 5-year survival rate of 51% and 25%, respectively.13 In this study, none of the patients with extrapelvic disease at the time of presentation were alive at 5 years. According to a recent SEER database study, stage is an independent prognostic factor for disease-specific survival (P < 0.001).8

Several studies suggest that tumor size may be an important prognostic factor.4,13 In a study by Abeler et al13 of uterine-confined tumors, size was associated with 5-year survival on univariate and multivariate analysis. On multivariate analysis, the relative risk of death was 2.7 (P < 0.01) for tumors greater than 100 mm.13

In patients without macroscopic extension, the incidence of nodal metastases is estimated to be 4% to 11%.1,14 In a study by Giuntoli et al14 of 208 patients, nodal metastases were reported in 4 of the 36 patients who underwent lymphadecetomy, 3 of whom had extrauterine disease. Survival was similar for patients with stage I disease and histologically negative nodes and those with stage I disease who did not undergo lymphadenectomy. Similarly, Kapp et al9 found that lymph nose status was not statistically significant on multivariate analysis in 5-year disease-specific survival.

Age, mitotic count, and grade have also been studied, although data are conflicting on the prognostic value of these factors. Older age has also been reported to negatively impact outcome in some studies.15 However, other studies have not demonstrated an association between age and prognosis.1 Mitotic count was reported to be the only significant prognostic factor associated with progression-free survival in patients with LMS in a GOG study of early-stage uterine sarcoma (P = 0.03).1 However, several studies have failed to demonstrate this association. Tumor grade has also been evaluated as a potential prognostic factor. Whereas studies have showed that grade was associated with survival,8 a GOG study failed to find any correlation between grade and progression-free survival.1

In a recent series, Rauh-Hain et al16 studied 167 patients with LMS and found that size greater than or equal to 11 cm and mitotic count of 25/10 HPF or greater were independent predictors of poor overall survival in patients with stage I–II disease. For patients with stage III–IV disease, mitotic count of 25/10 HPF or greater was an independent predictor of overall survival.16

Iasonos et al17 recently explored a large retrospective cohort of LMS patients and devised a nomogram to predict 5-year overall survival for individual patients. The nomogram is based on age at diagnosis, tumor size, histologic grade, uterine cervix involvement, extrauterine spread, distant metastases, and mitotic index. The nomogram was subsequently externally validated.

Back to Top | Article Outline

TREATMENT

Early-Stage Disease

Total hysterectomy (TH) and bilateral salpingo-oophorectomy (BSO) are recommended for patients with LMS grossly confined to the uterus. The recommendation for BSO in premenopausal women with LMS should be individualized. In a case-control study of 25 women who underwent BSO and 25 who opted for ovarian preservation, both recurrence-free and disease-free survival were comparable.13 In a study with stage I–II LMS patients younger than 50 years, BSO was not linked to 5-year disease-free survival8; yet, it is unclear in this study how many women underwent BSO before LMS diagnosis.

As discussed previously, the risk for nodal involvement without obvious extrauterine extension is low,1,13 and lymphadenectomy does not seem to alter survival for early-stage patients.7,13 Therefore, lymphadenectomy is not recommended routinely unless nodes seem grossly abnormal or extrauterine disease is present at the time of surgery.

Back to Top | Article Outline

ADJUVANT THERAPY

Systemic Therapy

Several studies have investigated the role of adjuvant therapy in patients with stage I–II LMS; yet, the impact of any adjuvant therapy on survival remains elusive. Early studies suggested no change in overall or progression-free survival with chemotherapy for this group of patients. However, in a recent study, 25 patients with high-grade and completely resected LMS were treated with gemcitabine plus docetaxel.18 Fifty-nine percent of the patients with stage I–II LMS remained progression-free at 3 years.18 However, this study is limited by small patient size and the lack of a control arm. Currently, the GOG, in collaboration with Cancer Research UK and the European Organization of Research and Treatment of Cancer, is conducting a study comparing gemcitabine plus docetaxel, followed by doxorubicin to observation only in patients with high-grade, completely resected stage I LMS.

Back to Top | Article Outline

Radiation Therapy

Whereas some studies previously advocated for external beam radiation for reducing recurrence, Reed et al19 published a prospective randomized trial of 224 women older than 13 years after early-stage uterine sarcoma resection who did and did not receive pelvic radiation. These results suggest that there is no benefit associated with the use of radiation therapy. In the retrospective study by Wong et al,20 32 of the 69 patients with LMS were treated with adjuvant radiation therapy. In multivariate analysis, radiation therapy reduced local recurrence (3-year local recurrence, 19% vs 39%; P = 0.019) and improved overall survival (3-year overall survival, 69% vs 35%; P = 0.025).20 In this study, positive surgical margins increased the risk for local recurrence, and despite use of radiation therapy, a large proportion of patients developed distant metastases.20 Further studies are necessary to better elucidate which patients with LMS may benefit from adjuvant radiation therapy.

Back to Top | Article Outline

ADVANCED-STAGE/RECURRENT DISEASE

In patients with unresectable disease, surgery may have limited use. Not only does surgery expose these patients to the potential morbidity and mortality of an extensive procedure but also delays the initiation of systemic therapy. Palliative TH may be considered in patients with severe local symptoms. Limited data support resection to no gross residual disease given improved survival in patients with complete cytoreduction when compared with those with remaining disease.14 For patients diagnosed with LMS on final pathologic review, secondary surgery can be considered, including complete hysterectomy, trachelectomy, and/or BSO.

In the unfortunate case of tumor morcellation, surgical exploration is recommended to remove any residual peritoneal disease. According to the current Society of Gynecologic Oncology statement on morcellation, fewer than 1 of the 1000 women who undergo hysterectomy for leiomyomas will have an underlying malignancy. All patients should be evaluated for the possibility of coexisting uterine or cervical malignancy before morcellation, and other options such as mini-laparotomy or morcellation within a laparoscopic bag should be considered.21 Oduyebo et al22 recently reported a series of 21 patients who were found to have LMS on final pathology after a procedure involving morcellation. In this study, surgical reexploration upstaged 28.5% of the patients.

Patients with recurrent disease may be considered for secondary surgery. In a study of 128 patients with recurrent LMS, median time to recurrence was 1.3 years.23 Secondary cytoreductive surgery, prolonged time to recurrence, and localized recurrence were significantly and independently associated with improved disease-specific survival. Interestingly, neither chemotherapy nor radiation showed improved outcomes in patients with recurrent LMS.23

Although the value of adjuvant chemotherapy remains unproven, most advanced-stage LMS patients receive systemic therapy. Combination treatment with gemcitabine and docetaxel currently has the highest reported response rate of 36%.24 Although other cancers have shown improved outcomes when bevacizumab, the anti-VEGF monoclonal antibody, is added to a standard chemotherapy regimen, this does not seem to be the case for LMS tumors. Recent data from a phase III double-blinded placebo-controlled trial by Hensley et al25 suggested that there was no benefit in overall survival or progression-free survival with the addition of bevacizumab to the standard regimen of gemcitabine and docetaxel.

Studies suggest that gemcitabine and docetaxel are also effective as a second-line therapy. In GOG 131G, 51 patients with progression after first-line treatment were treated with gemcitabine and docetaxel for an overall response rate of 27% with 52% of patients noted to be disease-free at 6 months.26

Many other agents are currently being studied to determine their efficacy against LMS tumors. Pazopanib, an oral multikinase inhibitor, is approved in the United States for the treatment of metastatic soft tissue sarcoma and is being studied for LMS patients after progression on anthracycline-based therapy. Trabectedin, a superoxide producer, is also currently being studied. The role of these agents in LMS is still unproven. Ongoing work also continues in establishing the role of anastrozole and letrozole for patients with ER/PR positive disease. Mutlimodality treatment using both chemotherapy agents as well as pelvic RT is also currently being studied and only appropriate in the setting of clinical trials.

Back to Top | Article Outline

CONCLUSIONS

Although rare, uterine LMSs are extremely aggressive tumors with high recurrence rates, even when confined to the uterine corpus at the time of diagnosis. When diagnosed preoperatively, patients should be counseled for TH, typically with BSO unless premenopausal. Complete surgical cytoreduction should be considered when feasible. Lymphadenectomy should be undertaken only in patients with suspicious nodes or extrauterine disease. Most patients are diagnosed with LMS postoperatively and should be counseled for completion hysterectomy/BSO in the case of myomectomy. These patients may also be counseled to consider a second surgical procedure for attempted optimal cytoreduction, in the event of metastatic disease unresected at the time of initial surgery. Systemic therapy should be considered for patients who are not appropriate surgical candidates because of functional status or tumor burden.

For early-stage (I–II) disease, close observation and surveillance are recommended as there are limited and conflicting data to support adjuvant chemotherapy. There is no role for radiation therapy for these patients. In patients with advanced-stage (III–IV) disease, chemotherapy with gemcitabine and docetaxel should be considered. For patients with recurrent disease, therapy should be chosen based on the patient’s functional status and previous treatment-related toxicities.

Future studies investigating the role of advanced imaging to differentiate benign leiomyomas from LMS preoperatively may provide valuable prognostic data. Nomograms may also play a key role in prognostic discussions with patients. Ongoing biomedical research as to the pathways and receptor status may provide essential insight into the pathogenesis of these tumors and shed light on possible targeted therapies.

Back to Top | Article Outline

REFERENCES

1. Major FJ, Blessing JA, Silverberg SG, et al. Prognostic factors in early stage uterine sarcoma: a Gynecologic Oncology Group study. Cancer. 1993; 71: 1702–1709.
2. Prat J. FIGO staging for uterine sarcomas. Int J Gynaecol Obstet. 2009; 104: 179.
3. Toro JR, Travis LB, Wu HJ, et al. Incidence patterns of soft tissue sarcomas, regardless of primary site, in the surveillance, epidemiology and end results program, 1978–2001: an analysis of 26,758 cases. Int J Cancer. 2006; 119: 2922–2935.
4. Wickerham DL, Fisher B, Wolmark N, et al. Association of tamoxifen and uterine sarcoma. J Clin Oncol. 2002; 20: 2758–2765.
5. Chiang S, Oliva E. Recent developments in uterine mesenchymal neoplasms. Histopathology. 2013; 62: 124–137.
6. D’Angelo E, Pratt J. Uterine sarcomas: a review. Gynecol Oncol. 2010; 116: 131–139.
7. Mills AM, Ly A, Balzer BL. Cell cycle regulatory markers in uterine atypical leiomyoma and leiomyosarcoma: immunohistochemical study of 68 cases with clinical follow-up. Am J Surg Pathol. 2013; 37: 634–642.
8. Rose PG, Piver MS, Tsukada Y, et al. Patterns of metastasis in uterine sarcoma. An autopsy study. Cancer. 1989; 63: 935–938.
9. Kapp DS, Shin JY, Chan JK. Prognostic factors and survival in 1396 patients with uterine leiomyosarcomas: emphasis on impact of lymphadenectomy and oophorectomy. Cancer. 2008; 112: 820–830.
10. Bansal N, Herzog TJ, Burke W, et al. The utility of preoperative endometrial sampling for the detection of uterine sarcomas. Gynecol Oncol. 2008; 110: 43.
11. Kitajima K, Murakami K, Kaji Y, et al. Spectrum of FDG PET/CT findings of uterine tumors. Am J Roentgenol. 2010; 195: 737–744.
12. Sharma P, Kumar R, Singh H, et al. Role of PET-CT in detecting recurrence in patients with uterine sarcoma: comparison with conventional imaging. Nucl Med Commun. 2012; 33: 185–190.
13. Abeler VM, Royne O, Thoresen S, et al. Uterine sarcomas in Norway. A histopathological and prognostic survey of a total population from 1970 to 2000 including 419 patients. Histopathology. 2009; 54: 355–364.
14. Giuntoli RL II, Metzinger DS, DiMarco CS, et al. Retrospective review of 208 patients with leiomyosarcoma of the uterus: prognostic indicators, surgical management, and adjuvant therapy. Gynecol Oncol. 2003; 89: 460–469.
15. Wu TI, Chang TC, Hsueh S, et al. Prognostic factors and impact of adjuvant chemotherapy for uterine leiomyosarcoma. Gynecol Oncol. 2006; 100: 166–172.
16. Rauh-Hain JA, Oduyebo T, Diver EJ, et al. Uterine leiomyosarcoma: an updated series. Int J Gynecol Cancer. 2013; 23: 1036–1043.
17. Iasonos A, Keung EZ, Zivanovic O, et al. External validation of a prognostic nomogram for overall survival in women with uterine leiomyosarcoma. Cancer. 2013; 119: 1816–1823.
18. Hensley ML, Ishill N, Soslow R, et al. Adjuvant gemcitabine plus docetaxel for completely resected stages I–IV high grade uterine leiomyosarcoma: Results of a prospective study. Gynecol Oncol. 2009; 112: 563–567.
19. Reed NS, Mangioni C, Malmström H, et al. Phase III randomised study to evaluate the role of adjuvant pelvic radiotherapy in the treatment of uterine sarcomas stages I and II: an European Organisation for Research and Treatment of Cancer Gynaecological Cancer Group Study (protocol 55874). Eur J Cancer. 2008; 44: 808–812.
20. Wong P, Han S, Sykes J, et al. Postoperative radiotherapy improves local control and survival in patients with uterine leiomyosarcoma. Radiat Oncol. 2013; 8: 128.
21. SGO statement on morcellation. Accessed February 21, 2014.
22. Oduyebo T, Rauh-Hain AJ, Meserve EE, et al. The value of re-exploration in patients with inadvertently morcellated uterine sarcoma. Gynecol Oncol. 2014; 132: 360–365.
23. Giuntoli RL, Garrett-Mayer E, Bristow RE, et al. Secondary cytoreduction in the management of recurrent uterine leiomyosarcoma. Gynecol Oncol. 2007; 106: 82–88.
24. Hensley ML, Blessing JA, Degeest K, et al. Fixed-dose rate gemcitabine plus docetaxel as second-line therapy for metastatic uterine leiomyosarcoma: a Gynecologic Oncology Group phase II study. Gynecol Oncol. 2008; 109: 323–328.
25. Hensley ML, O’Malley DM, Mannel RS, et al. A randomized phase III trial of gemcitabine + docetaxel + bevacizumab or placebo as a first-line treatment for metastatic uterine leiomyosarcoma (uLMS): a Gynecologic Oncology Group Study. Plenary at 3/2014 SGO.
26. Muss HB, Bundy B, DiSaia PJ, et al. Treatment of recurrent or advanced uterine sarcoma. A randomized trial of doxorubicin versus doxorubicin and cyclophosphamide (a phase III trial of the Gynecologic Oncology Group). Cancer. 1985; 55: 1648–1653.
Keywords:

Leiomyosarcoma; Uterine tumor; Review

© 2014 by the International Gynecologic Cancer Society and the European Society of Gynaecological Oncology.